Immunocore Holdings plc Cash Flows From Used In Financing Activities
Immunocore Holdings plc (IMCR) reported Cash Flows From Used In Financing Activities of GBP 9.84 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Cash Flow › Financing Activities
ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2023-08-10
- Immunocore Holdings plc cash flows from used in financing activities for the quarter ending 2022-12-31 was -1.19M GBP.
- Immunocore Holdings plc cash flows from used in financing activities for the quarter ending 2022-09-30 was 117.52M GBP.
- Immunocore Holdings plc cash flows from used in financing activities for the quarter ending 2021-12-31 was -2.06M GBP.
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 9 month | Cash Flows From Used In Financing Activities 12 month |
|---|---|---|---|---|
| 2023-06-30 | 9.84M GBP 6-K · filed 2023-08-10 | |||
| 2022-12-31 | -1.19M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 116.32M GBP derived: sum of 2 quarters · filed 2023-03-01 | 114.45M GBP 20-F · filed 2023-03-01 | |
| 2022-09-30 | 117.52M GBP derived: 6-K/A 9 month − 6-K 6 month · filed 2022-11-18 | 115.64M GBP 6-K/A · filed 2022-11-18 | ||
| 2022-06-30 | -1.87M GBP 6-K · filed 2023-08-10 | |||
| 2021-12-31 | -2.06M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 204.63M GBP 20-F · filed 2023-03-01 | ||
| 2021-09-30 | 206.69M GBP 6-K/A · filed 2022-11-18 | |||
| 2020-12-31 | 115.94M GBP 20-F · filed 2023-03-01 | |||
| 2019-12-31 | 55.13M GBP 20-F · filed 2022-03-03 | |||
| 2018-12-31 | 101.00K GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |